Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Hit By U.S. Generic Competition In 2010; Extends Share Buyback Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Revenues flat year on year, but profits up 5% in a year of cost savings and late-stage product disappointments.

You may also be interested in...



EU Pharma Ups Share Buybacks In 2012

Share buybacks are controversial in the biopharma industry, but European pharma companies, facing tough operating environments and pressures on near-term financials, are planning to invest in them in 2012 more than in recent years.

“Arimidex Direct” Program Will Provide Branded Cancer Drug To U.S. Patients For $40 A Month

Spurred on by patient requests for affordable access to the branded version of now generic anastrozole, AstraZeneca will partner with Express Scripts to provide the drug direct to patients at a fixed co-payment.

AstraZeneca Collaboration With Medical Research Council May Mean New Life For 22 Compounds

U.K.-based academic research teams will be able to apply to work with the AstraZeneca compounds free of charge and receive grant funding from MRC under the collaboration.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071770

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel